DermTech, Inc. (NASDAQ:DMTK – Get Free Report) CFO Kevin M. Sun sold 9,180 shares of the firm’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $1.93, for a total transaction of $17,717.40. Following the transaction, the chief financial officer now owns 283,361 shares of the company’s stock, valued at approximately $546,886.73. The transaction was disclosed in a document filed with the SEC, which is available at this link.
DermTech Stock Performance
Shares of DMTK stock opened at $1.94 on Friday. DermTech, Inc. has a 12 month low of $1.55 and a 12 month high of $6.44. The business’s 50 day moving average is $2.68 and its two-hundred day moving average is $3.00.
DermTech (NASDAQ:DMTK – Get Free Report) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.04). DermTech had a negative net margin of 853.02% and a negative return on equity of 99.14%. The company had revenue of $3.98 million for the quarter, compared to analyst estimates of $3.55 million. As a group, research analysts forecast that DermTech, Inc. will post -3.56 EPS for the current year.
Hedge Funds Weigh In On DermTech
Analysts Set New Price Targets
Separately, BTIG Research reduced their price objective on shares of DermTech from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, August 7th.
DermTech Company Profile
DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers.
- Five stocks we like better than DermTech
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Shutterstock is the Value Stock they don’t want you to know about
- What Are Dividend Challengers?
- 3 Low-Cost ETFs That Are Crushing SPY
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.